Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
CELC
CELC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CELC News
Celcuity Announces Efficacy Results of Gedatolisib in Advanced Breast Cancer
19h ago
Newsfilter
Boxer Capital Increases Stake in Celcuity
4d ago
Fool
Boxer Capital Increases Stake in Celcuity
4d ago
NASDAQ.COM
Surge in Options Trading Volume for ON Holding AG
Mar 02 2026
NASDAQ.COM
Apis Capital Increases Stake in Garrett Motion by 2.09 Million Shares
Feb 26 2026
Fool
Apis Capital Increases Stake in Garrett Motion
Feb 26 2026
NASDAQ.COM
Perceptive Advisors Increases Stake in Celcuity
Feb 22 2026
Fool
Perceptive Advisors Acquires 431,432 Shares of Praxis Precision Medicines
Feb 22 2026
Yahoo Finance
Perceptive Advisors Increases Stake in Celcuity
Feb 22 2026
Yahoo Finance
Perceptive Advisors Increases Stake in Celcuity
Feb 22 2026
NASDAQ.COM
Celcuity Inc. Options Trading Analysis
Feb 13 2026
NASDAQ.COM
Soleus Capital Increases Stake in Celcuity
Feb 13 2026
Fool
Celcuity Director Sells $2.4 Million in Shares via Indirect Transaction
Feb 06 2026
Fool
Celcuity to Participate in Biotech Summit 2026
Feb 04 2026
Newsfilter
Xpeng Inc Reports Disappointing Delivery Numbers, Stock Drops
Feb 02 2026
Benzinga
Celcuity (CELC) Receives FDA Priority Review for Gedatolisib, Target Action Date July 17, 2026
Jan 20 2026
seekingalpha
Show More News
